Spero Therapeutics (FRA:2HA) Long-Term Capital Lease Obligation : €2.60 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Spero Therapeutics Long-Term Capital Lease Obligation?

Spero Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was €2.60 Mil.

Spero Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Mar. 2024 (€3.24 Mil) to Jun. 2024 (€2.98 Mil) and declined from Jun. 2024 (€2.98 Mil) to Sep. 2024 (€2.60 Mil).

Spero Therapeutics's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€5.29 Mil) to Dec. 2022 (€4.68 Mil) and declined from Dec. 2022 (€4.68 Mil) to Dec. 2023 (€3.51 Mil).

Spero Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Spero Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics Long-Term Capital Lease Obligation Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

4.16

5.66

5.29

4.68

3.51

Spero Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															3.86	3.51	3.24	2.98	2.60

Spero Therapeutics (FRA:2HA) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Spero Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (FRA:2HA) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

SPRO:USA 2HA:Germany

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics Headlines

No Headlines